Codiak BioSciences to Present at the Evercore ISI 3rd Annual HealthCONx Conference

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

CAMBRIDGE, Mass., Nov. 23, 2020 (GLOBE NEWSWIRE) — Codiak BioSciences, Inc. (NASDAQ: CDAK), a clinical-stage company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that its President and Chief Executive Officer, Douglas E. Williams, Ph.D., will participate in a fireside chat at the Evercore ISI 3rd Annual HealthCONx Conference. Details are as follows:

Evercore ISI 3rd Annual HealthCONx Conference
Date: Wednesday, December 2
Time: 4:45 p.m. ET

A live webcast of the fireside chat will be available on the Investors & Media section of the Codiak website at www.codiakbio.com. An archived replay will be available for approximately 90 days following the fireside chat.   

About Codiak BioSciences
Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need. By leveraging the biology of exosomes as natural intercellular transfer mechanisms, Codiak has developed its proprietary engEx Platform to expand upon the innate properties of exosomes to design, engineer and manufacture novel exosome therapeutic candidates. Codiak has utilized its engEx Platform to generate a deep pipeline of engineered exosomes aimed at treating a broad range of disease areas, spanning oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease.

Media Contact
Lindy Devereux
Scient PR
T: 646-515-5730
E: media@codiakbio.com

Investor Contact
Christine Labaree
Evergreen Communications
T: 650-600-1697
E: investor@codiakbio.com

Staff

Recent Posts

cbdMD Expands Oasis Social Tonics to Total Wine

Charlotte, North Carolina--(Newsfile Corp. - June 24, 2025) - cbdMD, Inc. (NYSE American: YCBD), a…

1 minute ago

MedsEngine Helps Medical Practices Unlock $30,000 Per Provider in Additional Annual Revenue

DAYTON, Ohio--(BUSINESS WIRE)--MedsEngine, a leader in chronic disease management software, announced today that medical practices…

56 minutes ago

Trially AI Taps Serial Entrepreneur Christian Smith as CRO to Expand AI Clinical Trial Enrollment Across U.S.

KANSAS CITY, Mo.--(BUSINESS WIRE)--#AIinHealthcare--Trially®, a breakthrough AI clinical trial recruitment technology to unlock faster qualified…

57 minutes ago

cultivate(MD) Announces Portfolio Company, Virtual Incision Corporation, Appoints Jim Alecxih as Chief Executive Officer

GRAND RAPIDS, Mich., June 24, 2025 /PRNewswire/ -- cultivate(MD), a leading medical device venture capital company, is…

1 hour ago

Brainomix and 3DR Labs Partner to Advance Stroke Care in the US Through Clinically Validated AI Imaging Solution

OXFORD, England and CHICAGO, Ill., June 24, 2025 /PRNewswire/ -- Today, Brainomix, a pioneer in…

1 hour ago

Cosmo to Unveil First-of-its-Kind Clinical Study on the Use of GI Genius(TM) with Apple Vision Pro at Rush University Medical Center

Dublin, Ireland--(Newsfile Corp. - June 24, 2025) - Cosmo Pharmaceuticals N.V. (“Cosmo”) today announced that…

5 hours ago